Table 2.
Candidate TE-derived isoform switching in cancer. (Examples are shown for individual TE-derived alternative splice events that are overexpressed in cancer compared to normal tissue.)
| clustera | gene | cancer type | %TEi-Nb | %TEi-Tc | event type |
|---|---|---|---|---|---|
| 467 | MYH11 | lung squamous cell carcinoma | 6.5 | 51.8 | Alt3 |
| 412 | CANT1 | stomach adenocarcinoma | 67.3 | 37.4 | exon |
| 132 | WHSC1 | stomach adenocarcinoma | 73.1 | 42.8 | exon |
| 412 | CANT1 | breast invasive carcinoma | 53.5 | 32.1 | exon |
| 154 | KMT2D | stomach adenocarcinoma | 21.3 | 31.8 | Alt5 |
| 397 | POLG | stomach adenocarcinoma | 34.8 | 54.6 | Alt3 |
| 397 | POLG | bladder urothelial carcinoma | 34.8 | 47.6 | Alt3 |
| 261 | PML | kidney renal papillary cell carcinoma | 57.2 | 70.3 | intron |
| 261 | PML | breast invasive carcinoma | 47.0 | 59.6 | intron |
| 261 | PML | kidney chromophobe | 65.5 | 75.8 | intron |
aCluster ID number corresponding to the distinct TE-derived alternative splicing event.
bRelative expression (percentage of total) for the TE-derived isoform in normal tissue.
cRelative expression (percentage of total) for the TE-derived isoform in tumour tissue.